First Trust Value Line Dividend Index Fund
Analysts’ Expectations for Sanofi
According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”
Teva Is Expected to See a Fall in Its Profit Margins in 2017
Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.
AvalonBay: What’s Driving the Dividend and Valuations?
AvalonBay’s revenue grew 7% in the first quarter, driven by rental and other income.
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug
On October 17, 2016, Teva and Regeneron announced that the FDA had placed the Phase 2 study for fasinumab on clinical hold.
Sanofi’s Consumer Healthcare and Generics Franchises
Sanofi’s (SNY) Consumer Healthcare franchise’s products include Allegra, Doliprane, and Nasacort. The segment reported a 3.1% decline in revenues at 905 million euros in 1Q16, compared to its 1Q15 revenues.
Sanofi: Analysts’ Recommendations on October 30
As of October 30, four analysts are tracking Sanofi. Two analysts recommend a “strong buy,” while two analysts recommend a “hold.”
GlaxoSmithKline’s Q3 2018 Earnings: Analysts’ Estimates
Analysts are expecting GlaxoSmithKline’s revenues to increase 2.3% to 8.02 billion pounds for the third quarter of 2018.
Novartis in Q3 2018: Analysts Expect Revenue Growth
Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018.
A Look at the Performance of Novartis’s Alcon
Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise.
How Novartis’s Sandoz Business Has Been Performing Recently
Sandoz, Novartis’s (NVS) generics business, is a market leader in differentiated generics.
How GlaxoSmithKline’s Pharmaceutical Business Performed
GlaxoSmithKline’s (GSK) Pharmaceutical segment includes various products from different therapeutic areas including respiratory products, HIV products, immuno-inflammation products, and established products.
Alcon Voluntarily Withdraws CyPass Micro-Stent from Global Market
On August 29, Alcon announced that it had voluntarily withdrawn the CyPass Micro-Stent on a global basis, effective immediately.
GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018
GlaxoSmithKline’s (GSK) Pharmaceuticals segment includes its HIV, respiratory, immuno-inflammation, and established products.
Why GlaxoSmithKline’s Q2 2018 Revenues Are Expected to Decline
The Pharmaceuticals segment is expected to report growth in operating revenues in Q2 2018 with a strong performance of new respiratory products.
How the Healthcare Sector’s Dividend Yield Stacks Up
The healthcare industry has an average dividend yield of 1.9%.
How Novartis’s Revenues Trended in 4Q17
Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017.
A Look at Ablynx and Sanofi’s Existing Partnership
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.
Trelegy Ellipta May Emerge as Major Growth Driver for GlaxoSmithKline
Trelegy Ellipta could enable GlaxoSmithKline to compete aggressively with other respiratory players such as Novartis (NVS).
How Is Novartis’s Tafinlar+Mekinist Positioned for 2018?
In 1Q17, 2Q17, and 3Q17, Tafinlar+Mekinist reported revenues of $187 million, $216 million, and $224 million, respectively.
Why Assurant Has a Positive Outlook despite a Weak 2017
Assurant’s (AIZ) revenue fell 27% and 18% in 2016 and 9M17, respectively.
Behind Novartis’s Respiratory Drug Performance in 3Q17
In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.
A Look at Assurant, Another Top Dividend Grower
Assurant’s revenue and earnings in 2015 and 2016 Assurant’s (AIZ) revenue fell 1% and 27% in 2015 and 2016, respectively. Its US revenue rose in 2015 before falling in 2016, and its international revenue fell in both years, along with its net earned premiums, net investment income, and net realized gains on investments. Its fees and other […]
Sanofi’s Kevzara Could Be Solid Addition to Rheumatoid Arthritis
Launched in US markets in June 2017, Kevzara (sarilumab), Sanofi (SNY) and Regeneron’s (REGN) IL-6 receptor antibody, has received favorable feedback from the physician community.
What Led to Sempra Energy’s Sharp Fall in Dividend Yield?
Sempra Energy’s revenue for the first half of 2017 rose 7.0%, driven by every segment.
How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.
What Analysts Recommend for Novartis in September 2017
Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”
What Could Drive TechnipFMC’s Dividend Yield
How TechnipFMC intends to maintain its yield FMC Technologies and Technip merged to become TechnipFMC (FTI) in 2017, an international provider of subsea, onshore, offshore, and surface projects. The synergy aims to combat the challenges of low oil prices and a challenging outlook through cost cutting and the enhancement of efficiency. The company recorded 51% revenue […]
GlaxoSmithKline Reported Revenue Growth in 2Q17
GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
Inside Novartis’s 2Q17 Revenues
Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
Bristol-Myers Squibb’s Valuation after 2Q17 Earnings
Bristol-Myers Squibb (BMY) met Wall Street analysts’ estimate for EPS at $0.74. It also surpassed the estimates for revenues.
Dividend Yield of Franklin Resources
Franklin Resources (BEN) has recorded consistent growth in dividends since at least March 1982.
Sanofi’s General Medicines and Consumer Healthcare in 2Q17
General Medicines Sanofi’s (SNY) generic business contributed ~5.1% of its total revenue in 2Q17. The business reported revenue of 442 million euros in 2Q17, an 8% decrease from 2Q16. Revenue fell due to lower sales in US markets, European markets, and emerging markets. This fall was partially offset by the growth in the rest of […]
A Look at Sanofi’s Post-2Q17 Valuation
Sanofi (SNY), one of the world’s largest pharmaceutical companies, reported operational growth of 5.5% to reach revenue of 8.7 billion euros in 2Q17.
Target’ s Performance as a Dividend Aristocrat
Target’s (TGT) sales for 2016 fell 6.0% due to lower comparable store sales and weak store traffic.
Have Intel and Procter & Gamble Been Able to Increase Dividends?
Intel (INTC) released its 2Q17 results on July 27, 2017. The company’s revenue and EPS for the first half of 2017 rose 8.5% and 72.0%, respectively.
GSK’s 2Q17 Earnings: Pharmaceuticals Segment
GSK’s Pharmaceuticals segment’s contribution to the company’s total revenues was 59.5% in 2Q17.
Arbor Realty Trust’s Dividend Growth Prospects
Arbor Realty Trust (ABR) paid 74.1% of its earnings as dividends in 2016 compared to 56.7% in 1Q17.
Unpacking GlaxoSmithKline’s 2Q17 Revenue Expectations
Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds.
Novartis in 2Q17: Performance of Innovative Medicines
The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.
Novartis’s 2Q17 Estimates: Innovative Medicines Segment
The overall contribution of Novartis’s (NVS) Innovative Medicines segment is ~67.0% of its total revenues.
The Top Dividend-Growing Healthcare and Industrials Stocks
The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms.
Dividend Growth for Qualcomm and Crown Castle International
Qualcomm (QCOM) recorded a year-over-year decline in revenues for 2Q17 after growth in the preceding quarter.
What Happened to Novartis’s Valuation after 1Q17?
Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues.
Sanofi’s Generics and Consumer Healthcare Business in 1Q17
Sanofi’s (SNY) Generics business contributes ~5% to the group’s total revenues.
Novartis’s 1Q17 Estimates: Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology.
Why Sanofi’s Consumer Healthcare and Generics Segment Still Matters
Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016.
Could Novartis’s CTL019 Capture Significant Market Share?
Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel.
Are Sanofi’s Established Prescription Products Adding Up?
Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016.
Inside Sanofi’s Overall Revenue Performance in 2016
Sanofi (SNY) reported a YoY (year-over-year) revenue growth of ~1.2% at constant exchange rates for 2016.
Why Entresto Could Become Key Growth Driver for Novartis in 2017
Novartis (NVS) expects modest prescription growth for its heart failure drug, Entresto, in 1Q17.
Novartis’s Valuation Compared to Its Peers’
Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.
What Will Drive AstraZeneca’s Oncology Revenues in 2017?
In 2016, AstraZeneca’s (AZN) poly ADP-ribose polymerase (or PARP) inhibitor, Lynparza, managed to report revenues close to $218 million.
Growth of AstraZeneca’s Oncology Segment in 2016
The revenues for AstraZeneca’s (AZN) Oncology segment rose ~20% at constant exchange rates in 2016.
These Prescription Products Matter to Sanofi’s Growth
Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.
Novartis’s Valuation after the 4Q16 Results
On January 31, 2017, Novartis was trading at a forward PE multiple of ~15.2x. Based on its last-five-year multiple range, this is neither high nor low.
Inside Novartis’s Generics Performance in 4Q16
Sandoz, the Generics segment of Novartis (NVS), is second-largest generic medicines provider worldwide and number one in differentiated generics.
Analysts Expect Negative Growth for Novartis in 4Q16
Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products.
How Did Novartis’s Innovative Medicines Segment Perform?
The overall contribution of the innovative medicines segment was ~67% at $8,173 million for 3Q16.
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016
On October 26, 2016, AstraZeneca (AZN) announced that Lynparza managed to demonstrate a superior clinical profile in the Phase 3 SOLO-2 trial.
Teva’s Research Pipeline to Culminate in Many New Drug Launches?
Teva Pharmaceutical’s (TEVA) generic research pipeline is expected to result in more than 30 first-to-file (or FTF) launches in 2016 and 2017.
Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics
In 3Q16, Teva Pharmaceutical Industries (TEVA) reported increased price erosion of about 7.0% for its US-based business compared to 3Q15.
Performance of Novartis’s Innovative Medicines Segment in 3Q16
Novartis’s (NVS) Innovative Medicines segment contributed ~67.0% at $8.2 billion for 3Q16.
Changes in Novartis’s Valuation for 3Q16
Based on the last five years’ multiple range, Novartis’s current valuation is neither high nor low. The PE multiple has ranged from ~9.0x to ~20.0x.
Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’
In his November Insights newsletter, Richard Bernstein stated, “It is incredible that investors have basically been wallflowers during the second longest bull market of the post-war period.”
Inside AstraZeneca’s Oncology Segment Growth in 3Q15
AstraZeneca’s (AZN) Oncology segment is another key company focus area. The segment’s contribution rose to over 17% in 3Q16.
Inside AstraZeneca’s Revenue Fall in 3Q16
For 3Q16, AstraZeneca (AZN) reported a 4.1% fall in its top line at $5.7 billion.
Richard Bernstein: Don’t Fear the Bear Market
A legitimate bull market In this series, we’ve taken a look at Richard Bernstein’s views on investors’ fear of an impending bear market. In Richard Bernstein Advisors’ October Insights newsletter, he rejects the notion that the current rise in US stocks (SPLV) (OEF) has been brought about only by the Fed’s easy monetary policy. In the […]
Volume Growth and Product Mix to Drive NVO’s Insulin Sales
From 2011 to 2015, Novo Nordisk’s (NVO) diabetes care franchise sales have risen at a compounded average growth rate (or CAGR) of approximately 11.5%.
Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk
With a 46% share of the global insulin market, Novo Nordisk (NVO) is currently a leading player in the diabetes care segment.
A Look at Teva’s Dominance in the Biosimilar Space
As one of the early entrants in biosimilars, Teva Pharmaceutical Industries (TEVA) has managed to become one of the biggest players in the biosimilar space.
Teva Pharmaceutical Leads in Global Generic Pharmaceutical Space
After the acquisition of Allergan’s generics business and divestitures, Teva Pharmaceutical has become a leading player in the global generic industry.
Analyst Price Targets and Recommendations for Sanofi
According to a Bloomberg consensus of five brokerage firms on September 12, 60.0% of analysts rated Sanofi as a “buy,” while 40% rated it as a “hold.”
How Sanofi’s Various Franchises Performed in 2Q16
Established Rx is Sanofi’s largest franchise, with a share of 30% of total sales in 2Q16 totaling 2.6 billion euros, or about $2.9 billion.
How Sanofi’s Franchises Could Perform into 2017
During the second quarter of 2016, Sanofi’s aggregate sales declined by 0.2% to about $10 billion. Its diabetes and cardiovascular franchise fell by 2%.
Understanding Sanofi’s Discounted Valuation
On September 8, 2016, Sanofi was trading at a forward PE multiple of 12.17x—at a greater discount than peers Eli Lilly, Merck & Company, and Novo Nordisk.
Why Is Sanofi Expanding in the CHC Space?
Sanofi (SNY) plans to become a leading company in the CHC business. The asset swap will exclude Boehringer Ingelheim’s CHC business in China.
Litigation Has Teva Pharmaceutical’s Copaxone 40 mg All Tied Up
Teva Pharmaceutical is currently facing litigations in which competitors are challenging the orange book patents it holds for Copaxone 40 mg.
Why AstraZeneca Reported Negative Growth in 2Q16
AstraZeneca reported a gradual shift of positive contributors from key drugs such as Nexium and Synagis to new products in growth platforms.
Is AstraZeneca’s Valuation Improving Compared to Peers?
AstraZeneca’s stock value has increased 11.9% over the last 12 months. Analysts estimate that it has the potential to return 17.8% over the next 12 months.
This Changed Sanofi’s Profitability in 2Q16
Sanofi reported a net profit of ~1.7 billion euros (about $1.9 billion) in 2Q16—a decline of 8.7% in net profits over 2Q15.
How Much Did Kellogg Return to Shareholders?
Kellogg announced a quarterly dividend of $0.50 per share on its common stock—paid on June 15 to shareowners of record at the close of business on June 1.
Why Analysts Think AstraZeneca’s Revenues Will Fall in 2Q16
AstraZeneca (AZN) reported an increase of 1% in its top line to $6.1 billion in its 1Q16 results.
How Do the Majority of Analysts Rate Novartis after 2Q16?
Novartis’s annual estimated EPS for 2016 came in at $4.80, with a fall of ~1.5% in annual revenues to ~$48.7 billion and a gross margin rising to 73.1%.
GlaxoSmithKline Segments That Drive Company’s Rising Revenues
Analysts expect a growth of ~7.8% in GlaxoSmithKline’s (GSK) 2Q16 revenues, to 6.4 billion British pounds.
Inside the Foreign Exchange Impact on Novartis’s Growth in 2Q16
Novartis (NVS) reported no change in revenues on a constant currency basis for 2Q16, as compared to 2Q15, in its earnings release on July 19, 2016.
Novartis’s Sandoz Division Accounts for 18% of Net Sales in 2015
Sandoz accounted for $9.2 billion, or 18%, of Novartis’s net sales during 2015.
Teva Expects to Maintain Profitability despite Tough Pricing Environment
Since February 2016, generic drug manufacturers, wholesalers, and distributors have been expressing increased concern over the expected price deflation in the industry.
Portfolio Construction in Interest Rate–Driven Bull Markets
In a falling interest rate environment, the PE ratio rises because investors are keen to increase the time horizon of their investments.
Trends for Sanofi Pasteur: The Human Vaccines Segment
Sanofi Pasteur, the Human Vaccines business of Sanofi (SNY), reported an 8.2% increase at constant exchange rates in its 1Q16 revenues at 625 million euros.
What’s Kellogg’s 2020 Vision Strategy?
Kellogg plans to return its “Kashi” brand to growth in 2016. It aims to lead in plant-based nutrition and win with “food forward” consumers.
Why Did Sandoz Report Operational Growth?
Sandoz is the generics arm of Novartis (NVS). For 1Q16, Sandoz contributed ~21.1% of the total revenue at $2.44 billion.
Lesinurad: A Selective Uric Acid Reabsorption Inhibitor for Gout
Lesinurad, originally developed by Ardea Biosciences, was acquired by AstraZeneca through the acquisition of Ardea in June 2012. It works to reduce the uric acid levels in gout patients.
A Methodology Overview of the First Trust Value Line Dividend Index Fund
First Trust Value Line Dividend Index Fund is a smart beta fund by First Trust that seeks to replicate the performance of the Value Line Dividend Index.
A Fund Flow Analysis of the First Trust Value Line Dividend Index Fund
Fiscal 2015 has seen a considerable falls in the First Trust Value Line Dividend Index Fund due to the weak economic environment and SPY’s poor performance.
Archer Daniels Midland Misses Consensus Earnings Estimates
Archer Daniels Midland reported earnings per share of $0.60 in 3Q15, missing consensus estimates by 18%. When compared to 3Q14, EPS has fallen by 30%.
A Comparative Analysis of DVY
The iShares Select Dividend ETF (DVY) is majorly invested in the utilities, financials, and consumer staples sectors.